XBIT · XBiotech Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | $0 | $4.01M | $18.39M | $44M | $0 | $0 | — | — | — | — | — | |
| — | — | — | $0 | $651K | $5.82M | $34.55M | $0 | $0 | — | — | — | — | — | |
| — | — | — | $0 | $3.36M | $12.57M | $9.45M | $0 | $0 | — | — | — | — | — | |
| — | — | — | — | 83.77% | 68.36% | 21.48% | — | — | — | — | — | — | — | |
| $40.94M | $47.39M | $37.76M | $32.85M | $31.54M | $28.27M | $9.53M | $24.09M | $15.73M | $26.42M | $42.49M | $31.31M | $14.33M | $7.94M | |
| $7.28M | $8.3M | $4.71M | $4.66M | $6.31M | $9.39M | $18.2M | $7.14M | $5.27M | $7.64M | $10.28M | $6.2M | $7.45M | $1.99M | |
| — | — | $42.47M | $37.51M | $37.85M | $37.66M | $27.73M | $31.23M | $20.99M | $34.06M | $52.76M | $37.51M | $21.78M | $9.93M | |
| -$48.22M | -$55.69M | -$42.47M | -$37.51M | -$34.49M | -$25.08M | -$18.28M | -$31.23M | -$20.99M | -$34.06M | -$52.76M | -$37.51M | -$21.78M | -$9.93M | |
| — | — | — | — | -860.1% | -136.36% | -41.54% | — | — | — | — | — | — | — | |
| $3.36M | $10.38M | $3.91M | $13.2M | $902K | -$376K | $5.45M | $749.69M | -$144K | $909K | $2000 | $27K | $54K | -$2000 | |
| -$44.86M | -$45.31M | -$38.56M | -$24.31M | -$33.59M | -$25.46M | -$12.83M | $718.45M | -$21.14M | -$33.15M | -$52.76M | -$37.48M | -$21.72M | — | |
| $273K | $235K | -$32K | $244K | -$688K | -$8.04M | -$1.61M | $49.82M | $0 | $0 | $0 | $0 | $0 | — | |
| -$45.13M | -$45.54M | -$38.53M | -$24.56M | -$32.9M | -$17.41M | -$11.22M | $668.63M | -$21.14M | -$33.15M | -$52.76M | -$37.48M | -$21.72M | -$9.93M | |
| — | — | — | — | -820.45% | -94.67% | -25.5% | — | — | — | — | — | — | — | |
| — | — | -$38.53M | -$25.38M | -$34.05M | -$16.71M | -$9.85M | $668.78M | -$20.63M | -$33.98M | -$52.5M | -$37.53M | -$21.74M | -$9.93M | |
| USD/shares | -$1.47 | -$1.49 | -$1.26 | -$0.81 | -$1.08 | -$0.58 | -$0.36 | $17.17 | -$0.59 | -$0.95 | — | — | — | — |
| USD/shares | — | -$1.49 | -$1.26 | -$0.81 | -$1.08 | -$0.58 | -$0.36 | $14.44 | -$0.59 | -$0.95 | — | — | — | — |
| shares | — | 30.49M | 30.46M | 30.44M | 30.44M | 30.04M | 30.82M | 38.95M | 35.8M | 34.88M | 32.4M | 30.8M | 24.16M | 22.22M |
| shares | — | 30.49M | 30.46M | 30.44M | 30.44M | 30.04M | 30.82M | 46.32M | 35.8M | 34.88M | 32.4M | 30.8M | 24.16M | 22.22M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2024: $14K in buybacks, $75M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 291 similar-size Biotechnology companies (of 524 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Manufacturing Revenue | $4,010,000 | $18,000,000 | $18,000,000 | $0 | $0 |
| Clinical Trial Service Revenue | $0 | $394,000 | $25,975,000 | $0 | $0 |
| Product And Service Other | — | — | $22,000 | $0 | $0 |